Can low brain-derived neurotrophic factor levels be a marker of the presence of depression in obese women?

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 2079-2086

  Guzel, Eda Celik ^a   Bakkal, Esra ^a   Guzel, Savas ^a   Eroglu, Hasan Emre ^a   Acar, Ayse ^a   Kuçukyalcin, Volkan ^a   Topcu, Birol ^a  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Brain Derived neurotrophic factor; Comorbidity; Obesity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYANOCOBALAMIN; INSULIN;

ADULT; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; OBESITY; PREDICTIVE VALUE; PREVALENCE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VITAMIN BLOOD LEVEL;

EID: 84908692925     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S72087     Document Type: Article

References (46)

1. Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity. Geneva: 1997 June 3–5.
2. Clinical guidelines on the identifcation, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res. 1998; 6 Suppl 2:S51–S209.
3. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–229.
4. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63(7):824–830.
5. Ramos LW, Murad N, Goto E, et al. Ischemia/reperfusion is an independent trigger for increasing myocardial content of mRNA B-type natriuretic peptide. Heart Vessels. 2009;24(6):454–459.
6. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238–258.
7. Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–235.
8. Resch M, Haasz P, Sido Z. Obesity as psychosomatic disease. European Psychiatry. 1998;13 Suppl 4:S315.
9. Castelnuovo-Tedesco P, Schiebel D. Studies of superobesity: I. Psychological characteristics of superobese patients. Int J Psychiatry Med. 1975;6(4):465–480.
10. Wiedemann K, Jahn H, Kellner M. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes. 2000;108(1):5–13.
11. Kellner M, Herzog L, Holsboer F, Wiedemann K. Circadian changes in the sensitivity of the corticotropin-releasing hormone-stimulated HPA system after arginine vasopressin and atrial natriuretic hormone in human male controls. Psychoneuroendocrinology. 1995;20(5):515–524.
12. Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ. 2002;324(7352):1512–1515.
13. Bell IR, Edman JS, Morrow FD, et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc. 1991;39(3):252–257.
14. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE. Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. J Psychosom Res. 2000;49(3):183–187.
15. Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TM, Hankey GJ. B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol. 2010;68(4):503–510.
16. Lazarou C, Kapsou M. The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract. 2010;16(3):161–166.
17. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4): 526–534.
18. Beck AT, Steer RA, Brown GK. BDI-II Beck Depression Inventory, 2nd edn. Swedish manual, Harcourt Assessment. Sandviken; 2008.
19. Beck AT, Steer RA. Beck Anxiety Inventory manual. San Antonio (TX): Psychological Corporation, Harcourt Brace & Company;1993.
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma. Diabetologia. 1985;28(7): 412–419.
22. van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx B W. Longitudinal relationship of depressive and anxiety symptoms with dyslipidemia and abdominal obesity. Psychosom Med. 2013;75(1):83–89.
23. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594–600.
24. Koizumi M, Watanabe H, Kaneko Y, et al. Impact of obesity on plasma B-type natriuretic peptide levels in Japanese community-based subjects. Heart Vessels. 2012;27(3):287–294.
25. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43(9):1590–1595.
26. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immu-noanalyzers: analytical and clinical study. Ann Clin Lab Sci. 2006;36(3):299–306.
27. Park SJ, Cho KI, Jung SJ, et al. N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. Korean Circ J. 2009;39(12):538–544.
28. Kim BH, Kim IJ, Cho KI, Kim SM, Lee HG, Kim TI. The infuence of diabetes on the relationship between N-terminal pro-B-type natriuretic peptide and body mass index. J Int Med Res. 2010;38(5):1737–1748.
29. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149(4): 744–750.
30. Ahlberg AC, Ljung T, Rosmond R, et al. Depression and anxiety symptoms in relation to anthropometry and metabolism in men. Psychiatry Res. 2002;112(2):101–110.
31. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004;164(20):2247–2252.
32. Black DW, Goldstein RB, Mason EE. Prevalence of mental disorder in 88 morbidly obese bariatric clinic patients. Am J Psychiatry. 1992;149(2):227–234.
33. Britz B, Siegfried W, Ziegler A, et al. Rates of psychiatric disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. Int J Obes Relat Metab Disord. 2000;24(12):1707–1714.
34. Ferketich AK, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. Am Heart J. 2005;150(1):132–136.
35. Wisén AG, Ekberg K, Wohlfart B, Ekman R, Westrin A. Plasma ANP and BNP during exercise in patients with major depressive disorder and in healthy controls. J Affect Disord. 2011;129(1–3):371–375.
36. Aguiar VB, Ochiai ME, Cardoso JN, et al. Relationship between depression, BNP levels and ventricular impairment in heart failure. Arq Bras Cardiol. 2010;95(6):732–737.
37. Parissis JT, Farmakis D, Nikolaou M, et al. Plasma B-type natriuretic peptide and anti-infammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail. 2009;11(10):967–972.
38. Lesman-Leegte I, van Veldhuisen DJ, Hillege HL, Moser D, Sanderman R, Jaarsma T. Depressive symptoms and outcomes in patients with heart failure: data from the COACH study. Eur J Heart Fail. 2009;11(12):1202–1207.
39. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159(12):2099–2101.
40. Platt AM, Egan AM, Berquist MJ, Dreyer ML, Babar G, Ugrasbul F. Health-related quality of life, depression, and metabolic parameters in overweight insulin-resistant adolescents. J Pediatr Health Care. 2013;27(2):120–126.
41. Shen Q, Bergquist-Beringer S. Relationship between major depression and insulin resistance: does it vary by gender or race/ethnicity among young adults aged 20–39 years? J Diabetes. 2013;5(4):471–481.
42. Kan C, Silva N, Golden SH, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36(2):480–489.
43. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley K W. From infammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
44. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40(4):171–176.
45. van Reedt Dortland AK, Vreeburg SA, Giltay EJ, et al. The impact of stress systems and lifestyle on dyslipidemia and obesity in anxiety and depression. Psychoneuroendocrinology. 2013;38(2):209–218.
46. Valtonen MK, Laaksonen DE, Laukkanen JA, et al. Low-grade infammation and depressive symptoms as predictors of abdominal obesity. Scand J Public Health. 2012;40(7):674–680.